A European primarily based drug company referred to as GW prescribed drugs is about to start its initial part of clinical experiments for the treatment of brain tumor Multiforme (GBM). It’s a biopharmaceutical company centered on learning, developing and commercializing novel medicine from its proprietary cannabinoid product platform.
According to the New England Journal of Medicine, GBM estimates for approximately 50% of the 22,500 new cases of brain cancer diagnosed in the United States alone each year. (1) Treatment with regards to brain cancer is very faulty which makes the research of cannabis oil and its effect on brain tumours crucial.
It’s about time, isn’t it? For various years now, pre-clinical study convoyed by multiple scientists and universities all over the world has proved that cannabinoids inhibit the viability of glioma cells both in vitro and in vivo. This happens through the method of necrobiosis, or programmed cell death. Cannabis oil has successfully shown tumour growth-inhibiting action and advancement in the therapeutic efficacy of temozolomide, a standard prescription for glioma. GW Pharmaceuticals has also followed this research and also conduct it themselves. As a result, they’ve shown tumour response to be positively associated with tissue levels of cannabinoids.
We are very excited about moving this compound into further human research and the probabilities of cannabinoids as new anti-cancer treatments. This is GW’s first clinical research of cannabinoids as a potential treatment to inhibit tumour growth. We believe this clinical program confirms the flexibility and broad application of GW’s cannabinoids platform to manage significant unmet therapeutic needs. – Dr Steven Wright, Director of Research and Development at GW
The investigation will involve 20 patients, it will be two-part research with an open-label phase to evaluate safety and tolerability of GW cannabinoids in combination with temozolomide, and a double-blind, randomized, placebo-controlled part with patients randomised to active or placebo.
The analysis objective is to assess the tolerability, safety, and pharmacodynamics of a mix of 2 principal cannabinoids, psychoactive substance and CBD in an exceedingly 1:1 allocation ration, together with temozolomide in patients with recurrent GBM.
Disclaimer: the principles contained here is not designed nor meant to be a substitute for professional medical advice, it is only achieved for educational confidences only. You should assume full responsibility for the way you decide to use this information on this blog.